Mesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Mesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2024 report and make more profitable business decisions.
Mesenchymal tumors represent a heterogenous group of neoplasms that include malignant, intermediate malignancy, and benign entities. Sarcomas are extremely rare, accounting for only 1% of malignancies in adults and up to 10-15% of malignancies in the paediatric population. They are characterized by a global incidence of 30-50 cases per million person-years and show a wide anatomic distribution. Rarely, mesenchymal lesions may occur in the gastrointestinal (GI) tract. Some of these entities occur almost exclusively in the GI tract, whereas other subtypes, when located in the GI tract, may assume distinct morphological features. The majority of sarcomas of the GI tract are represented by gastrointestinal stromal tumors (GISTs), which are the most common mesenchymal tumors in the stomach as well as in the small bowel. GIST represents a distinctive mesenchymal neoplasm sharing immunomorphologic features with the interstitial cell of Cajal. It exhibits an exclusive tropism for the GI tract.
The Mesenchymal Tumor Of The Gastrointestinal Tract drugs in development market research report provide comprehensive information on the therapeutics under development for Mesenchymal Tumor Of The Gastrointestinal Tract, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mesenchymal Tumor Of The Gastrointestinal Tract and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Mesenchymal Tumor Of The Gastrointestinal Tract | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 75 molecules, with 71 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Mesenchymal Tumor Of The Gastrointestinal Tract therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Mesenchymal Tumor Of The Gastrointestinal Tract pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Mesenchymal Tumor Of The Gastrointestinal Tract treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AB Science SAAdvanced Accelerator Applications SA
Advenchen Laboratories LLC
Allarity Therapeutics Inc
Alligator Bioscience AB
Alyra Therapeutics Inc
Arog Pharmaceuticals Inc
Ascentage Pharma Group International
Bayer AG
Beijing Immunochina Pharmaceuticals Co Ltd
BioAtla Inc
Blueprint Medicines Corp
Chang Gung Memorial Foundation
Chinese Academy of Sciences
Clinigen Ltd
Cogent Biosciences Inc
CStone Pharmaceuticals Co Ltd
Deciphera Pharmaceuticals Inc
DNAtrix Inc
Eisai Co Ltd
Eli Lilly and Co
Esperas Pharma Inc
F. Hoffmann-La Roche Ltd
Guangzhou Institute of Biomedicine and Health
Handok Inc
Hanmi Pharmaceuticals Co Ltd
Hefei Cosource Pharmaceutical Inc
Hoth Therapeutics Inc
IDRx Inc
Inhibrx Inc
Kinnate Biopharma Inc
Lotus Pharmaceutical Co Ltd
Mendus AB
Merck & Co Inc
Merck KGaA
NewBay Medical Technology Co Ltd
Ningbo Tai Kang Medical Technology Co Ltd
Novartis AG
Novelty Nobility Inc
Omeros Corp
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
Plexxikon Inc
Protheragen Inc
Qualigen Therapeutics Inc
Repare Therapeutics Inc
Sartar Therapeutics Ltd
Shanghai Affinity Biopharmaceutical Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shijiazhuang Yiling Pharmaceutical Co Ltd
Soricimed Biopharma Inc
Taivex Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Tarapeutics Science Inc
Theseus Pharmaceuticals Inc
TotalClarity Inc
Virocure Inc
Table of Contents
Table
Figures
Frequently asked questions